β-受体阻滞剂预防食管静脉曲张首次出血的应用进展
被引量:2
摘要
食管静脉曲张出血是肝硬化门脉高压症的严重并发症之一。在确立肝硬化诊断时,已有60%的失代偿期患者和30%处于代偿期的患者存在食管胃底静脉曲张[1]。形成静脉曲张的最低门静脉压力梯度值或与此相当的肝静脉压力梯度值(HVPG)的阈值,为10~12mmHg(1 mmHg≈0.133 kPa)。
出处
《现代实用医学》
2012年第8期955-958,共4页
Modern Practical Medicine
参考文献22
-
1D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension:A meta-- analytic review[J]. Hepatology, 1995,22 (1):332-354. 被引量:1
-
2The Northern Italian Endoscopic Club for the Study and Treatment of Esophageal Varices.Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices:a pros pective multicenter study[J].N Engl J Med, 1988, 319(15): 983-989. 被引量:1
-
3Vlachogiannakos J, Goulis J, Patch D. Primary prophlaxis for portal hyperten- sive bleeding in cirrhosis[J]. Aliment Pharmacol Ther, 2000, 14(7):851-860. 被引量:1
-
4Pagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: Natural history//Bosch J, Groszmarm R, eds.Por- tal Hypertension. Pathophysiology and Treatment [M]. Cambridge, MA:Black well Science, 1994:72-92. 被引量:1
-
5D'Amico G, Pagliaro L, Bosch J. Phar- macological treatment of portal hyperten- sion:an evidence-based approach[J].Sem- in Liver Dis, 1999, 19(4): 475-505. 被引量:1
-
6Bureau C, Peron JM, Alric L, et al. "A la Carte" Treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding[J]. Hepatology, 2002, 36(6): 1361-1366. 被引量:1
-
7Abraczinskas DR, Ookubo R, Grace ND, et al.Propranolol for the prevention of first esophageal variceal hemorrhage:a life- time commitment[J]. Hepatology, 2001, 34(6): 1096-1102. 被引量:1
-
8Lui HF, Stanley A J, Forrest EH, et al. Pri- mary prophylaxis ofvariceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate [J]. Gastroenterology, 2002,123(3):735-744. 被引量:1
-
9Garcia-Pagan JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the pre- vention of first varices bleed in patients who can not receive beta-blockers[J] .Gas- troenterology, 2001, 121(4):908-914. 被引量:1
-
10Vorobioff JD, Gamen M, Kravetz D, et al. Effects of long-term propranolol and Oc- treotide on postprandial hemodynamics in cirrhosis:a randomized controlled trial[J]. Gastroentrology, 2002, 122(4):916-922. 被引量:1
同被引文献40
-
1de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension [ J ]. J Hepatol, 2010, 53 (4): 762-768. 被引量:1
-
2Lebrec D, Nouel O, Corbic M, et al. Propranolol -- a medical treatment for portal hypertension? [ J]. Lancet, 1980, 2 (8187): 180-182. 被引量:1
-
3Villanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding [ J ]. Gastroenterology, 2009, 137 ( 1 ) : 119-128. 被引量:1
-
4Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis [ J ]. J Gastroenterol, 2012, 47 (5) : 561-568. 被引量:1
-
5Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis [ J ]. Am J Gastroenterol, 2007, 102 (9): 2086-2102. 被引量:1
-
6Bosch J. Carvedilol for portal hypertension in patients with cirrhosis[J]. Hepatology, 2010, 51 (6) : 2214-2218. 被引量:1
-
7Reiberger T, Ulbrich G, Ferlitseh A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol [ J ]. Gut, 2013, 62 (11): 1634-1641. 被引量:1
-
8Sinagra E, Perricone G, D' Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[ J ]. Aliment Pharmacol Ther, 2014, 39 (6) : 557-568. 被引量:1
-
9Bureau C, Peron JM, Alric L, et al. " A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding [J]. Hepatology, 2002, 36 (6): 1361-1366. 被引量:1
-
10Liu S. Management of upper gastrointestinal bleeding from portal hypertension: Elective or emergency operation? [J]. Pak J Med Sci, 2014, 30 (3) : 574-577. 被引量:1
引证文献2
-
1段旭红,诸葛宇征,张峰.非选择性β受体阻滞剂预防食管胃静脉曲张破裂出血的研究进展[J].胃肠病学,2015,20(10):629-631. 被引量:3
-
2段旭红,张峰,张明,徐慧,贺奇彬,王轶,陈培忠,诸葛宇征.普萘洛尔降低肝硬化患者肝静脉压力梯度的影响因素[J].中华消化杂志,2016,36(3):150-154. 被引量:7
二级引证文献10
-
1莫如聪,林宁,李世聪,赖广顺,刘扬浪,赖名恩.内镜下曲张静脉套扎联合药物治疗肝硬化并发食管静脉曲张破裂出血的疗效[J].慢性病学杂志,2022(6):879-881. 被引量:2
-
2肖朗.乙肝病毒载量对门静脉压力的影响及其分子机制探讨[J].海南医学院学报,2016,22(9):857-859. 被引量:1
-
3秦小波.奥曲肽联合普萘洛尔治疗肝硬化上消化道出血及对患者血流量的影响[J].中国卫生标准管理,2017,8(17):69-71. 被引量:2
-
4程云凤,李熳,贺丽敏,丁钢.普萘洛尔治疗肝硬化食管胃底静脉曲张的临床效果分析[J].吉林医学,2017,38(12):2316-2317. 被引量:2
-
5张艳杰,高月秋,冯春,文锐,刘红,季先友.内镜套扎术联合β受体阻滞剂治疗食管静脉曲张破裂出血的临床疗效分析[J].中国实用医药,2018,13(1):69-70. 被引量:4
-
6王欣,乔瑞,王永席,翟红兵,王莎莎.普萘洛尔及卡维地洛降低肝硬化性食管静脉曲张患者肝静脉压力梯度的差异分析[J].临床药物治疗杂志,2018,16(10):50-53. 被引量:5
-
7赵林华,尚建中.卡维地洛降低乙型肝炎肝硬化患者肝静脉压力梯度的效果及影响因素分析[J].肝脏,2018,23(4):326-329. 被引量:1
-
8赵丹,付凤侠,余月菊.TIPS术联合奥曲肽治疗乙型肝炎肝硬化食管胃底静脉曲张出血的效果[J].肝脏,2019,24(12):1466-1468. 被引量:6
-
9陈小银,孔繁静,简维,牛彦锋,张万里,李芬.肝硬化食管胃静脉曲张普萘洛尔干预后血流动力学应答及无应答患者的特征分析[J].肝脏,2020,25(11):1191-1194. 被引量:2
-
10徐慧,张峰,张明,诸葛宇征.普萘洛尔对肝硬化门静脉高压患者血流动力学的影响和疗效观察[J].临床肝胆病杂志,2019,35(4):801-807. 被引量:8
-
1鲍沫章.真有那么多高血压患者吗——质疑现行的测血压方法[J].发明与创新(大科技),2003(6):34-37.
-
2张建红,聂占国,热合曼,薛静,郭现芳.奥曲肽联合特利加压素治疗肝硬化疗效及对患者肝静脉压力梯度影响的观察[J].中国医学装备,2015,12(9):92-95. 被引量:4
-
3汤善宏,秦建平,曾维政,徐辉,范泉水,蒋明德.肝硬化门静脉高压合并食管静脉曲张出血的风险评估[J].胃肠病学和肝病学杂志,2014,23(11):1255-1258. 被引量:15
-
4刘亮.卡维地洛和普萘洛尔对肝硬化胃底静脉曲张HVPG的影响[J].肝脏,2016,21(9):758-760. 被引量:5
-
5夏玉莲,张春清,王广川,冯华,张明艳.奥曲肽和特利加压素单用或联用对肝硬化患者肝静脉压力梯度的影响[J].临床肝胆病杂志,2015,31(2):214-218. 被引量:8
-
6Colecchia A,吴娜,李婉玉.脾硬度可能成为HCV感染肝硬化失代偿预测指标[J].临床肝胆病杂志,2014,30(8):721-721.
-
7马婉蓉,范国鑫,祁小龙,杨长青.肝静脉压力梯度研究进展[J].中华实用诊断与治疗杂志,2013,27(9):835-836. 被引量:3
-
8韩晓栋,霍丽娟,田玲琳.不同剂量依贝沙坦治疗大鼠门静脉高压症的实验研究[J].山西医科大学学报,2007,38(10):874-877.
-
9田相国,张春清.门静脉高压并食管胃底静脉曲张出血的治疗策略[J].临床肝胆病杂志,2015,31(3):354-356. 被引量:19
-
10田玲琳,霍丽娟,韩晓栋.不同剂量氯沙坦治疗大鼠肝硬化门静脉高压症的实验研究[J].山西医科大学学报,2007,38(11):978-980.